Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SLC6A4 | P31645 | 18/20 | 0.55 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.50 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.50 |
| ▸ | HTR2A | P28223 | 1/20 | 0.46 |
| ▸ | HTR2C | P28335 | 1/20 | 0.46 |
| ▸ | HTR2B | P41595 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6618227 | 1.00 | SLC6A4 (0.55) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6797661 | 0.90 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6617198 | 0.90 | SLC6A4 (0.54) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6614393 | 0.87 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6801031 | 0.87 | SLC6A4 (0.70) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6801805 | 0.85 | HTR2A (0.48) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6801807 | 0.85 | HTR2A (0.48) | SLC6A4SLC6A2SLC6A3HTR2AHTR2C | |
| SCHEMBL6613957 | 0.83 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6613961 | 0.83 | SLC6A4 (0.51) | SLC6A4SLC6A2SLC6A3 | |
| SCHEMBL6799374 | 0.82 | SLC6A4 (0.68) | SLC6A4SLC6A2SLC6A3HTR2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | claimed |
| EP-1373203-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | Bristol-Myers Squibb Company (US) | 2004-01-02 | — | — | EP | claimed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | claimed |
| WO-2002079152-A1 | CYCLOPROPYLINDOLE DERIVATIVES AS SELECTIVE SEROTONIN REUPTAKE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2002-10-10 | — | — | WO | claimed |
| US-6822100-B2 | REACTING N-SULFONYL-3-VINYLINDOLE WITH RUTHENIUM COMPLEX IN PRESENCE OF ETHYL DIAZOACETATE AND TOLUENE; PSYCHOLOGICAL, SEXUAL, AND EATING DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-11-23 | — | — | US | disclosed |
| US-6777437-B2 | ANTIDEPRESSANTS, ANXIOLYTIC AGENTS. SEXUAL DISORDERS | BRISTOL-MYERS SQUIBB COMPANY | 2004-08-17 | — | — | US | disclosed |
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | MATTSON RONALD J (US) | 2004-07-22 | — | — | US | disclosed |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2003-04-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040143003-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR1A, HTR1D, TPH1 | SLC6A4 16/4885SLC6A2 85/4885SLC6A3 46/4885 |
| US-20030073849-A1 | Cyclopropylindole derivatives as selective serotonin reuptake inhibitors | HTR5A, HTR1A, HTR2C | SLC6A4 10/4885SLC6A2 48/4885SLC6A3 34/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.